What does the Five Year Forward View mean for pharma?
December 6, 2016 | Five Year Forward View, STPs
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.
Introduction to the 5YFV
When it was launched in October 2014, the Five Year Forward View (5YFV) was hailed as one of the most radical changes in the management and organisation of NHS England since its inception in 1948. Designed by NHS England and five partner organisations, it aims to put an end to the age-old divide between GPs with patients, and consultants with hospitals, and develop new, integrated and cost efficient models of care that suit local needs. In doing so, it aspires to create a sustainable NHS that continues to be funded by the taxpayer, is free at the point of use and able to meet the evolving needs of patients, now and in the future.
How can pharma capitalise on the 5YFV?
The 5YFV is dramatically changing the way that NHS services are run, particularly at a local level. One of the biggest changes here is the planned introduction of STPs – Sustainability and Transformation Plans – in 2017, which will help to deliver 5YFV by providing blueprints for delivering services locally. Instead of taking a one-size fits all approach to healthcare provision, STPs will see the commissioner/provider split replaced by local planning and management within 44 areas across England called ‘footprints’. These area-specific, whole-system plans will identify the health needs of their populations and define how they should be addressed quickly and effectively at a local level. Understanding the bigger picture in terms of how STPs will affect areas such as NHS structure, leadership, commissioning, KPIs, efficiency, procurement and patient pathways is crucial for pharma. The industry also needs to get to grips with the priorities and primary objectives of the individual 44 STPs. Armed with this knowledge, the industry should look to offer tailored solutions that fit in with the aspirations of individual STPs and will help them to fulfil the needs of their local patient populations.
Sharing best practice – how can pharma help?
Sharing best practice is key to accelerating the pace of change within the NHS and since October 2011, NHiS, which is part of Wilmington Healthcare, has been helping to do this through its Mental Health Commissioning Network conferences. The events, which are being sponsored this year by Lundbeck Ltd, Shire Ltd and Sunovion, bring like-minded people together to discuss and exchange ideas on how to treat people with mental health problems in a more integrated way. Wherever possible, they involve locally identified Chairs plus the Strategic Clinical Networks, Academic Health Science Networks and Public Health England. They provide an ideal opportunity for pharma companies to get involved in shaping patient pathways and improving NHS services in line with the objectives of 5YFV.
Conclusion
Since its inception in 2014, 5YFV has been dramatically changing the way that NHS services are run, particularly at local level, and further major changes will occur when STPs are introduced next year. In the midst of this upheaval, there are golden opportunities for pharma to get involved in redesigning NHS services. The key is to keep abreast of the changes, understand the bigger picture and find ways to utilise its expertise to add value.
Sue Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is director of NHS insight, both at Wilmington Healthcare. www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare
How can pharma engage with key decision-makers in new, collaborative NHS care models?
Paul Midgley, Sue Thomas, Steve How and Oli Hudson, of Wilmington Healthcare, explore how pharma should adapt its approach
HSJ Awards open for entry with promise to champion NHS on its 70th anniversary
HSJ Awards open for entry with promise to champion NHS on its 70th anniversary
Wilmington Healthcare survey finds many doctors fear the NHS will fall victim to another ransomware attack
Following the ransomware attack that wreaked havoc on NHS IT systems last year and resulted in major disruption to patient care, the majority of doctors surveyed by healthcare intelligence provider...
Innovative NHS suppliers scoop HSJ Partnership Awards
Winners include pharma, medtech, healthcare consultants and IT specialists. Innovative pharma and medtech companies have been honoured in an awards scheme run by Health Service Journal (HSJ), the news and...
Managing local population needs is key for the NHS
Steve How, Paul Midgley and Sue Thomas, of Wilmington Healthcare, explore population-based planning in the NHS and what this means for pharma
Large-scale NHS commissioning models require new partnership approach from pharma
Steve How, Paul Midgley and Sue Thomas, of Wilmington Healthcare, explore how pharma should respond to the NHS’s move towards more collaborative, joined up working
Leading NHS suppliers highlighted in shortlist for new HSJ awards
The finalists for the first HSJ Healthcare Partnership Awards have been announced. The awards serve to recognise and celebrate those suppliers who work in partnerships with the NHS to drive...
Shining a light on the true cost of patient care
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore how the proposed national patient data sharing scheme would change the NHS
How can pharma engage with the top performing STPs?
The recent announcement by Health Secretary Jeremy Hunt on which Sustainability and Transformation Partnerships (STPs) would benefit from a share of the £325m capital funding allocated in the Spring Budget,...